Amylyx Pharmaceuticals, Inc.

AMLXNASDAQHealthcare● Active

$13.01

$-0.31(-2.33%)

Market Cap$1.1B

P/E Ratio—

52W High$18.605

52W Low$4.76

Avg Volume1.1M

Open$13.51

Beta-0.16

Free Cash Flow Financials Revenue

Amylyx Pharmaceuticals, Inc. (AMLX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AMLX · free cash flow · updated Jun 8, 2026

Core FCF metrics

AMLX · FCF · TTM · margin & CAGR

Free cash flow was −$123.5M for FY2025 (fiscal year ending 2025-12-31), up 26.4% year-over-year

FY2025 Free Cash Flow−$123.5M▲ +26.4% YoY

Trailing 12M (TTM)−$120.5Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AMLX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$123.3M(0M)−$123.5M▲ +26.4%—

FY2024−$167.6M(0M)−$167.8M▼ 1671.5%-192.1%

FY2023$11.9M(1M)$10.7M▲ +105.9%2.8%

FY2022−$179.9M(3M)−$182.4M▼ 142.7%-820.5%

FY2021−$74.8M(0M)−$75.2M▼ 104.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AMLX · P/FCF · FCF yield · FCF per share

Amylyx Pharmaceuticals, Inc. (AMLX) reported negative free cash flow of −$0.12B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

AMLX · cash flow statement · operating / investing / financing

For FY2025, Amylyx Pharmaceuticals, Inc. generated −$123.3M in operating cash flow and spent 0M in capital expenditures, yielding −$123.5M in free cash flow.

Operating Activities

−$123.3M

Cash from core business operations

2025-12-31

Investing Activities

+$14.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$257.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$123.3M) − |CapEx| (0M) = FCF (−$123.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AMLX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Amylyx Pharmaceuticals, Inc.YOU

AMLX

−$123.5M+26.4%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Amylyx Pharmaceuticals, Inc. (AMLX) reported free cash flow of −$123.5M for FY2025 (fiscal year ending 2025-12-31), up 26.4% year-over-year.

Based on available data, Amylyx Pharmaceuticals, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $10.7M in FY2023.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AMLX free cash flow · 8 questions

Amylyx Pharmaceuticals, Inc. free cash flow was −$123.5M for FY2025, up 26.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$120.5M.

AMLX free cash flowAMLX FCFAMLX FCF 2025AMLX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Amylyx Pharmaceuticals, Inc. · Amylyx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026